PTIX
Protagenic Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.75
−1.64%Year over year
Reported trailing growth
- Revenue
- +100.0%
- EBITDA
- +52.8%
- EBIT
- +30.1%
- EPS
- +165.6%
- Free cash flow
- +20.2%
- Operating cash flow
- +20.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -29.7%
- EBIT
- -2.3%
- Net income
- +6.7%
- EPS
- —
- Free cash flow
- +1.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026